Alex Bataller, MD, PhD
Department of Leukemia, Division of Cancer Medicine
About Dr. Alex Bataller Torralba
As an Assistant Professor at the University of Texas MD Anderson Cancer Center (MDACC), my research is dedicated to advancing our understanding of the biology and clinical outcomes of leukemias, with a particular focus on myelodysplastic syndromes (MDS). I possess a solid background in hematology, with specialized training in malignant hematologic disorders. During my hematology residency, I investigated genetic prognostic factors in acute leukemia and myelodysplastic syndromes, resulting in several peer-reviewed publications and forming the basis of my PhD thesis on AML prognostication. Following my residency, I was awarded two competitive research grants—the Emili Letang Award and the SEHH Investigation Grant—which supported the development and validation of a preclinical model for CAR T-cell therapy targeting AML at the Josep Carreras Leukemia Research Institute in Barcelona. In addition to leading this project, I contributed to numerous collaborative studies within the laboratory, resulting in several scientific publications and further strengthening my expertise in basic and translational hematology research. To enhance my scientific and clinical expertise, I completed two master’s degrees in Hematopoietic Transplantation and Molecular Oncology and developed advanced proficiency in statistical analysis and programming using R and Python. In 2022, I joined the Leukemia Fellowship Program at MDACC, where I broadened my clinical knowledge in leukemia care and continued to engage in high-impact research. My commitment to excellence was recognized with the Clinical Resident/Fellow Excellence Award and the Research Fellow of the year Award in 2024. Currently, I am an active member of the MDS research group at MDACC, contributing to both clinical and translational studies aimed at improving outcomes for patients with MDS. As a physician-scientist in Dr. Guillermo Garcia-Manero’s laboratory, I am pursuing research that bridges basic science and clinical application in the MDS field, furthering my long-term goal of translating scientific discoveries into improved therapeutic strategies for patients with hematologic malignancies.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
My research interests focus on understanding the biology underlying myeloid diseases such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). By improving our understanding of these diseases, we aim to develop more effective treatments for patients
Clinical Interests
My clinical team and I care for patients with leukemia and related bone marrow malignancies, with a particular focus on clonal hematopoiesis (CH), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, and acute myeloid leukemia (AML).
Education & Training
Degree-Granting Education
| 2022 | University of Barcelona, Barcelona, ES, Translational Medicine, PhD |
| 2014 | University of Barcelona, Barcelona, ES, MD |
Postgraduate Training
| 2022-2024 | Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2019-2020 | Master's Degree, Molecular Oncology, Rey Juan Carlos University, Madrid |
| 2018-2019 | Masters' Degree, Hematopoietic stem cell transplantation, University of Valencia, Valencia |
| 2015-2019 | Fellow, Hematology and Hemotherapy, Hospital Clinic of Barcelona, Barcelona |
Licenses & Certifications
| 2025 | Faculty Temporary License |
Experience & Service
Faculty Academic Appointments
Pre-doctoral Researcher, August Pi i Sunyer Biomedical Research institute (IDIBAPS) and Josep Carreras Leukemia Research Institute, Barcelona, 2019 - 2022
Administrative Appointments/Responsibilities
Chief fellow, Leukemia Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2024
Chief resident, Hematology Residency Program, Hospital Clinic de Barcelona, Barcelona, 2018 - 2019
Elected member of the Education Commission, Hospital Clinic de Barcelona, Barcelona, 2017 - 2019
Other Professional Positions
Hematology and Immunology lecturer, Academia de estudios AMIR, Madrid, 2016 - 2022
Student Mentor, Academia de estudios AMIR, Madrid, 2014 - 2015
Editorial Activities
Reviewer, “Annals of Hematology” journal, 2024 - 2024
Reviewer, “Leukemia and Lymphoma” journal, 2024
Reviewer, “BMC Cancer” journal, 2024 - 2024
Reviewer, “Cancer” journal, 2023 - 2024
Reviewer, “Clinical Lymphoma, Myeloma and Leukemia” journal, 2023
Reviewer, “European Journal of Hematology” journal, 2023
Reviewer, “Clinical Reviews in Oncology/Hematology” journal, 2023 - 2024
Reviewer, “Leukemia Research” journal, 2023 - 2024
Reviewer, “Bone Marrow Transplantation” journal, 2020
Reviewer, Journal, 2020 - Present
Honors & Awards
| 2024 | Best Research Fellow, Department of Leukemia, The University of Texas MD Anderson Cancer Center |
| 2024 | Clinical Resident/Fellow Excellence Award for Teamwork, MD Anderson Cancer Center |
| 2020 | MSD Grant for the most outstanding resident of the promotion, Hospital Clinic de Barcelona, Barcelona, Spain |
| 2019 | Investigation grant, Spanish Foundation of Hematology and Hemotherapy, Valencia, Spain |
| 2019 | Excellence scholarship, Spanish Association against Cancer (AECC), Madrid, Spain |
| 2018 | Emili Letang Residency Award, Hospital Clínic de Barcelona, Barcelona, Spain |
| 2018 | Bolsa de Viaje, Spanish Society of Hematology and Hemotherapy, Madrid, Spain |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III. Poster. ASH. Orlando, Florida, US.
- 2025. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes. Conference. ASH. Orlando, Florida, US.
- 2025. Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia. Conference. ASH. Washington, District of Columbia, US.
- 2025. Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center. Conference. ASH. Washington, District of Columbia, US.
- 2025. Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial. Conference. ASH. Washington, District of Columbia, US.
- 2025. Impact of NPM1 co-mutation on outcomes in RAS-mutated Acute Myeloid Leukemia. Conference. ASH. Washington, District of Columbia, US.
- 2025. Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes. Poster. ASH. Washington, District of Columbia, US.
- 2025. Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome. Conference. ASH. Washington, District of Columbia, US.
- 2024. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies. Conference. ASH. Washington, District of Columbia, US.
- 2024. Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Conference. ASH. San Diego, California, US.
- 2024. Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia. Conference. ASH. Washington, District of Columbia, US.
- 2024. Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Conference. ASH. Washington, District of Columbia, US.
- 2024. Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy. Conference. ASH. Washington, District of Columbia, US.
- 2024. Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials. Poster. ASH. Washington, District of Columbia, US.
- 2024. Genetic dynamics and outcomes of AML at first relapse Hematology/Oncology Grand Rounds. Invited. Chicago, IL, US.
- 2023. Mutational and Cytogenetic Dynamics at Diagnosis and Relapse in Acute Myeloid Leukemia: Influence of Intensity and Type of Treatment. Conference. ASH. San Diego, US.
- 2023. Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: P. ASH. Washington, District of Columbia, US.
- 2023. Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria. Conference. ASH. Washington, District of Columbia, US.
- 2023. Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax. Conference. ASH. Washington, District of Columbia, US.
- 2023. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML). Conference. ASH. Washington, District of Columbia, US.
- 2023. Acute Myeloid Leukemias: Clinical and Epidemiological: Poor Outcome of Patients with Acute Myeloid Leukemia in First Relapse Underscores the Need for Effective Initial Treatment. Poster. ASH. Washington, District of Columbia, US.
- 2023. Acute Myeloid Leukemias: Clinical and Epidemiological: NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage. Conference. ASH. Washington, District of Columbia, US.
- 2023. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study. Conference. ASH. Washington, District of Columbia, US.
- 2023. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia. Conference. ASH. Washington, District of Columbia, US.
- 2023. Acute Myeloid Leukemias: Clinical and Epidemiological: Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens. Conference. ASH. Washington, District of Columbia, US.
- 2023. Outcomes Research-Myeloid Malignancies: Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting. Poster. ASH. Washington, District of Columbia, US.
- 2023. Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort. Conference. ASH. Washington, District of Columbia, US.
- 2023. Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML). Poster. ASCO. Alexandria, Virginia, US.
- 2022. 637.Myelodysplastic Syndromes - Clinical and Epidemiological: Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome. Conference. ASH. Washington, District of Columbia, US.
- 2022. 509.Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Short Telomere Syndromes and Inherited Predisposition to Bone Marrow Diseases: The MDACC Experience. Poster. ASH. Washington, District of Columbia, US.
- 2022. 632.Chronic Myeloid Leukemia: Clinical and Epidemiological: Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia. Poster. ASH. Washington, District of Columbia, US.
- 2021. 703. Cellular Immunotherapies: Basic and Translational: Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Poster. ASH. Washington, District of Columbia, US.
- 2020. Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). Poster. ASH. Orlando, Florida.
International Presentations
- 2024. PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX AND GILTERITINIB IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA. Invited. European Hematology Association Meeting 2024. Madrid, ES.
- 2024. Understanding and facing R/R AML. Invited. II Annual Meeting of the CETLAM group. Barcelona, ES.
- 2023. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 mutations Update in diagnosis and management of acute myeloid leukemia. Invited. Barcelona, ES.
- 2023. KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS. Poster. The Hague, NL.
- 2023. SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. Poster. The Hague, NL.
- 2023. IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE. Poster. The Hague, NL.
- 2023. CD84-TARGETED CART-CELL THERAPY: A NOVEL STRATEGY FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES. Poster. The Hague, NL.
- 2023. EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE. Poster. The Hague, NL.
- 2023. CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS. Poster. The Hague, NL.
- 2023. EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS. Poster. The Hague, NL.
- 2023. Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Conference. EHA. The Hague, NL.
- 2023. PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA. Invited. European Hematology Association Meeting 2023. Frankfurt, DE.
- 2022. IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY. Poster. The Hague, NL.
- 2021. test. Poster. EHA, US.
- 2020. VALIDATION OF THE EUROPEAN LEUKEMIANET 2017 AML PROGNOSTIC CLASSIFICATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA IN A RISK-ADAPTED TREATMENT PROTOCOL (CETLAM 2012). Poster. EHA. The Hague, NL.
- 2019. IMPACT OF DNMT3A MUTATIONAL STATUS IN MOLECULAR MEASURABLE RESIDUAL DISEASE CLEARANCE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1. Poster. The Hague, NL.
Formal Peers
- KMT2A-Partial tandem duplications (MLL-PTD) in AML. Barcelona, ES.
- Design and validation of a CD123-directed CAR-T model for relapse/refractory acute myeloid leukemia. Barcelona, ES.
- CLL progression and transformation in the ibrutinib era. Barcelona, ES.
- Immunotherapy in acute myeloid leukemia. Barcelona, ES.
- Anaplastic lymphoma with peripheral blood expression. Barcelona, ES.
- ALK negative Anaplastic lymphoma. Barcelona, ES.
- Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL). Barcelona, ES.
Grant & Contract Support
| Date: | 2020 - 2022 |
| Title: | Investigation grant FEHH |
| Funding Source: | Spanish Foundation of Hematology and Hemotherapy |
| Role: | Predoctoral researcher |
| Date: | 2019 - 2020 |
| Title: | Emili Letang Residency Award |
| Funding Source: | Hospital Clinic of Barcelona |
| Role: | Predoctoral researcher |
Selected Publications
Peer-Reviewed Articles
- Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, Bazinet A, Bouligny IM, Senapati J, Haddad FG, Borthakur G, Sasaki K, Short NJ, Yilmaz M, Montalban-Bravo G, Tang G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian H, Jabbour E. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
- Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, Hammond D, Bouligny IM, Swaminathan M, Issa G, Short N, Daver N, DiNardo CD, Kadia T, Jabbour E, Ravandi F, Roboz GJ, Savona M, Griffiths EA, McCloskey J, Odenike O, Oganesian A, Keer HN, Azab M, Kantarjian H, Garcia-Manero G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J 15(1):50, 2025. e-Pub 2025. PMID: 40164584.
- Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
- Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
- Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Bataller, A, Garrido, A, Guijarro, F, Oñate, G, Díaz-Beyá, M, Arnan, M, Tormo, M, Vives, S, de Llano, MQ, Coll, R, Gallardo, D, Vall-Llovera, F, Escoda, L, Garcia-Guiñon, A, Salamero, O, Sampol, A, Merchan, B, Bargay, J, Castaño-Díez, S, Esteban, D, Oliver-Caldés, A, Rivero, A, Mozas, P, López-Guerra, M, Pratcorona, M, Zamora, L, Costa, D, Rozman, M, Nomdedeu, J, Colomer, D, Brunet, S, Sierra, J, Esteve, J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia. Blood Advances 6(4):1193-1206, 2022. e-Pub 2022. PMID: 34911079.
- Bataller A, Onate G, Diaz-Beya M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldes A, Lopez-Guerra M, Pratcorona M, Zamora L, Villamon E, Roue G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol 191(1):52-61, 2020. e-Pub 2020. PMID: 32510599.
- Bataller A, Garrote M, Oliver-Caldes A, Lopez-Guerra M, Colomer D, Aymerich M, Camos M, Vega-Garcia N, Diaz-Beya M, Esteve J. Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness. Br J Haematol 185(4):755-757, 2019. e-Pub 2019. PMID: 30334573.
- Bataller A, Combalia A, Garcia-Herrera A, Estrach T, Matutes E. Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma. Br J Haematol 185(2):205, 2019. e-Pub 2019. PMID: 30613940.
Review Articles
- Bataller A, Short NJ, Daver N, Yilmaz M, Kantarjian H, Ravandi F. Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy. Curr Oncol Rep 27(9):1097-1105, 2025. e-Pub 2025. PMID: 40748523.
- Bataller A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G. The role of TGFbeta in hematopoiesis and myeloid disorders. Leukemia 33(5):1076-1089, 2019. e-Pub 2019. PMID: 30816330.
Editorials
- Bataller A, Issa GC. Menin and BCL2 inhibitors- shaken and stirred. Haematologica 111(5):1513-1514, 2026. PMID: 41568517.
Letters to the Editor
- Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
- Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica 109: 293-297, 2024.
- Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127: 107044, 2023.
- Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64: 746-749, 2023.
- Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, Chevallier P, Zaliova M, Zuna J, Mozas P, Magnano L, Grardel N, Cornillet-Lefebvre P, Fu JF, Shih LY, Boneva T, Nacheva E, Bea S, Lopez-Guerra M, Bueno C, Menendez P, Esteve J, Larghero P, Meyer C, Marschalek R. KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints. Blood Adv 5: 5617-5620, 2021.
Patient Reviews
CV information above last modified July 10, 2026